<DOC>
	<DOCNO>NCT02559388</DOCNO>
	<brief_summary>In study hemodialysis patient underwent dialysis thrice weekly screen uremic pruritus 80 patient least refractive pruritus lead sleep daily activity disorder enroll study . These patient least course therapy without proper response . After proper informing patient take testimonial patient enter study . Then patient randomize case control group . In case group , patient take montelukast 10 milligram daily control group take placebo 30 day . Other antipruritic antiinflammatory medication stop one week prior start treatment . Calcium , phosphorous , urea , creatinine , highly sensitive CRP ( hsCRP ) , Parathyroid Hormone ( PTH ) , hemoglobin kt/V measure begin end study . pruritus severity assess Detailed Pruritus Score introduce Duo Visual Analogue Score begin end study group . Sleep disorder score severity add crude score begin end study change measure analyze .</brief_summary>
	<brief_title>Montelukast Treatment Uremic Pruritus</brief_title>
	<detailed_description>Montelukast antileukotrien receptor antagonist seem effective antipruritic medication via block inflammatory pathway .</detailed_description>
	<mesh_term>Renal Insufficiency</mesh_term>
	<mesh_term>Pruritus</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<mesh_term>Montelukast</mesh_term>
	<criteria>hemodialysis patient refer dialysis center least hemodialysis thrice weekly presence uremic pruritus patient least refractive pruritus lead sleep disorder compromise daily activity patient take course antipruritic treatment proper response presence pruritus less three month kt/V less 1.2 presence pruritus due cause uremic state presence pruritic disease ; malignancy ; cholestasis ; hepatitis B C infection treatment corticosteroid presence anemia hemoglobin less 10</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2015</verification_date>
</DOC>